An observational study in Short Bowel Syndrome (SBS), sponsored by Takeda. Recruiting at 4 sites in China. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by Takeda · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Short Bowel Syndrome by Takeda — 1 open to participants now, 3 under way, 1 of them phase 3. Short Bowel Syndrome · Takeda.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the only one that started in 2026, is one of 8 observational ones, and was the 26th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 26 studies in Short Bowel Syndrome by Takeda is open now, in 1 country.
By country, each count listing its studies:
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 12 is below the median of 53 across 36 observational studies indexed under Short Bowel Syndrome.
Median enrollment 22 across the 18 interventional studies, 59 across the 8 observational. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 155 (87%) have results posted.
2 of the studies in Short Bowel Syndrome by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
| NCT07319832TakedaA Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome | 2027-04-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Short Bowel Syndrome by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Short Bowel Syndrome (SBS) is a rare condition that happens when a large part of the bowel (also called intestine) is missing or has been removed because of illness or surgery. In children, SBS means that the intestine cannot absorb enough food, water and important part of food the body needs (called nutrients) because a big part of it has been removed, bypassed or did not develop normally at birth and the children need support through a vein (parenteral support or PS) for more than 42 days to stay healthy and keep their energy. SBS in children is defined mainly by how well the intestine works and how long the children need this support, not just by how long the intestine is.
The main aim of the study is to learn how well the teduglutide works in children and teenagers with SBS and who need PS. Another aim is to find out how well teduglutide works for participants to lower the amount of PS needed. Also, the study wants to learn more about how safe teduglutide is in children and teenagers with SBS who need PS.
The study will review data already existing in the medical records of participants as well as collect new data during the study.
The study population consists of Chinese pediatric participants with SBS who are dependent on PS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Signs of active, severe, or unstable clinically significant hepatic impairment during the screening or baseline period, indicative by any of the following laboratory test results:
Alanine Aminotransferase (ALT) >=7 × ULN
For Participants with Gilbert's disease:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who completed the 24-week teduglutide treatment period before enrollment will have their clinical data collected retrospectively from their medical records.
Other: No Intervention
Participants who initiated treatment before the study start date but have not completed the 24-week teduglutide treatment period at the time of enrollment will have their clinical data collected retrospectively before enrollment and prospectively after enrollment.
Other: No Intervention
Participants who will initiate the teduglutide treatment period after enrollment will have their clinical data collected prospectively for 48 weeks.
Other: No Intervention
No Intervention
Percentage of Participants Who Achieve at Least a 20% Reduction from Baseline in Weekly Parenteral Support (PS) Volume at Week 24
Percentage of participants who achieve at least a 20 percent (%) reduction from baseline in weekly PS volume at Week 24 will be reported.
Time frame: At Week 24
Number of Participants Able to Completely Wean off PS Support at Week 24
Number of participants who are able to completely wean off PS support at Week 24 will be reported.
Time frame: At Week 24
Absolute Change from Baseline in PN/Intravenous (IV) Support Volume
Absolute change from baseline in PN/IV support volume will be reported.
Time frame: Baseline up to Week 24
Percent Change From Baseline in PN/IV Support Volume
Percent change from baseline in PN/IV support volume will be reported.
Time frame: Baseline up to Week 24
Absolute Change From Baseline in PN/IV Support Calories
Absolute change from baseline in PN/IV support calories will be reported.
Time frame: Baseline up to Week 24
Percent Change From Baseline in PN/IV Support Calories
Percent change from baseline in PN/IV support calories will be reported.
Time frame: Baseline up to Week 24
Absolute Change From Baseline in Plasma Citrulline
Absolute change from baseline in plasma citrulline will be reported.
Time frame: Baseline, Week 24
Percent Change From Baseline in Plasma Citrulline
Percent change from baseline in plasma citrulline will be reported.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Enteral Nutrition (EN) Support Volume
Absolute change from baseline in EN support volume will be reported.
Time frame: Baseline up to Week 24
Percent Change From Baseline in EN Support Volume
Percent change from baseline in EN support volume will be reported.
Time frame: Baseline up to Week 24
Absolute Change From Baseline in EN Support Calories
Absolute change from baseline in EN support calories will be reported.
Time frame: Baseline up to Week 24
Percent Change From Baseline in EN Support Calories
Percent change from baseline in EN support calories will be reported.
Time frame: Baseline up to Week 24
Change From Baseline in Hours per day of PN/IV Support
Change from baseline in hours per day of PN/IV support will be reported.
Time frame: Baseline up to Week 24
Change From Baseline in Days per Week of PN/IV Support
Change from baseline in days per week of PN/IV support will be reported.
Time frame: Baseline up to Week 24
Percentage of Participants with at Least a 20% Reduction From Baseline in PN/IV Volume
Percentage of participants with at least a 20% reduction from baseline in PN/IV volume will be reported.
Time frame: Baseline up to Week 24
Change in Body Weight
Change in body weight will be reported.
Time frame: Baseline up to Week 24
Change in Height
Change in height will be reported.
Time frame: Baseline up to Week 24
Change in Head Circumference
Head circumference will be measured in participants 36 months of age and younger.
Time frame: Baseline up to Week 24
Change in Height Z-score
Height is measured using Z-score. Z score is calculated as (\[observed value/M\]\^L-1)/S\*L, where observed value is the child's height. The L, M, and S values vary according to the child's sex and age.
Time frame: Baseline up to Week 24
Change in Weight Z-score
Weight is measured using Z-score. Z score is calculated as (\[observed value/M\]\^L-1)/S\*L, where observed value is the child's weight. The L, M, and S values vary according to the child's sex and age.
Time frame: Baseline up to Week 24
Change in Body Mass Index (BMI)
BMI is a simple measure that uses a participant's weight and height to estimate whether they are underweight, normal weight, overweight, or obese. It is calculated as weight in kilograms (kg) divided by height in meters squared (kg/m\^2). Change in BMI will be reported.
Time frame: Baseline up to Week 24
Change in BMI Z-score
BMI is measured using Z-score. Z score is calculated as (\[observed value/M\]\^L-1)/S\*L, where observed value is the child's BMI. The L, M, and S values vary according to the child's sex and age.
Time frame: Baseline up to Week 24
Number of Participants with Adverse Events (AEs). Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have a causal relationship withthis treatment. An AE can therefore be any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product (investigational or marketed), whether or not considered related to treatment with the medicinal product. SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, or is an important medical event. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the product or program.
Time frame: Up to 50 weeks
Number of Participants with Clinically Significant Change in Vital Sign Values
Vital signs will include measurement of temperature, heart rate, blood pressure and respiratory rate. Any clinically significant change in vital signs will be determined at the investigator's discretion.
Time frame: Up to 24 weeks
Body Weight in Participants Dependent on PS
Body weight in kg will be collected and reported.
Time frame: Baseline up to Week 24
Head Circumference in Participants Dependent on PS
Head circumference in participants 36 months of age and younger will be collected and reported.
Time frame: Baseline up to Week 24
Height in Participants Dependent on PS
Height in centimeters (cm) will be collected and reported.
Time frame: Baseline up to Week 24
Trends on Growth Chart
Trends on growth chart will be collected and reported.
Time frame: Baseline up to Week 24
Urine Output Determined up to Week 24
Collected and calculated values of urine output will be recorded over a 48-hour period of PN/IV and EN stability before every clinic visit and within 1 week of implementing a change in the PN/IV prescription.
Time frame: Baseline up to Week 24
Fecal Output Measured by Volume
Collected and calculated values of fecal output should be recorded over a 48-hour period of PN/IV and EN stability before every clinic visit and within 1 week of implementing a change in the PN/IV prescription.
Time frame: Baseline up to Week 24
Fecal Output Measured by Number of Bowel Movements per Day
Fecal output should be recorded over a 48-hour period of PN/IV and EN stability before every clinic visit and within 1 week of implementing a change in the PN/IV prescription.
Time frame: Baseline up to Week 24
Number of Participants with Gastrointestinal-specific Testing
Gastrointestinal-specific testing will include colonoscopy or sigmoidoscopy or upper gastrointestinal (GI) endoscopy, abdominal ultrasound, fecal occult blood testing (FOBT), upper gastrointestinal series small bowel follow-through (UGI SBFT).
Time frame: Baseline up to Week 24
Number of Participants With Clinically Significant Changes in Physical Examinations
Physical examination will include assessing the participants physical status. (general surface, skin, head and neck, chest \[heart, lungs, breasts\], abdomen \[gastrointestinal, liver and gallbladder\], back, urinary system, limbs, nervous system, lymph nodes, etc.). Any clinically significant change in physical examination will be determined at the investigator's discretion.
Time frame: Up to 24 weeks
Number of Participants With Clinically Significant Changes in Laboratory Values
Laboratory parameters will include hematology, chemistry and urinalysis. Any clinically significant change in laboratory values will be determined at the investigator's discretion.
Time frame: Up to 24 weeks
Number of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Parameters
The 12-lead ECG will be evaluated. Any clinically significant change in ECG assessment will be determined at the investigator's discretion.
Time frame: Up to 24 weeks
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.